Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1

• Status: Completed
• Trial end date: 2017-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This is an open, controlled, prospective, proof-of-concept study, in 7 patients presenting NF1 and cutaneous neurofibromas. This study will include three treatment visits to the study center and three follow-up visits. Treatment will consist of two stages: neurofibroma microporation using the laser device, followed by topical application of one drop of diclofenac 25mg/ml on the surface of the neurofibroma; followed by re-application of one drop of diclofenac, twice daily, for three days. The applications subsequent to the first application will be performed by the patients. Subjects will return to the study center at three day intervals (Assessments 2 & 3) for new microporation and topical diclofenac application, followed by at-home topical diclofenac application for three more days. Assessment 4 will take place 3 days after Assessment 3. Assessment 5 will take place 7 days after the end of the treatment period and Assessment 6 at 30 days after the last application of study drug. The primary efficacy variable in this study is the inflammatory process with the presence of tissue necrosis. The primary safety variable is the occurrence of adverse events considered to be associated with the study drug, occurring during the treatment period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundação Educacional Serra dos Órgãos
• Treatments: Diclofenac

Criteria

Inclusion Criteria:

• Adults of both genders, between the ages of 18 and 65;

• NF1, diagnosed clinically by a neurologist, dermatologist, or other specialist knowledgeable about the disease, and defined as:

A known mutation in the gene coding for neurofibromin

or, the presence of 2 of the following 7 clinical manifestations of NF1:

• ≥ 6 café-au-lait macules on the body with diameters greater than 15mm in the greatest diameter;

• two or more neurofibromas of any type or one plexiform neurofibroma

• inguinal or axillary freckling

• two or more Lisch nodules (iris hamartomas)

• optic glioma

• a distinct osseous lesion, such as sphenoid wing dysplasia, pseudoarthrosis of the tibia, macrocephaly, or scoliosis

• a first-degree relative with NF1

• Presence of 4 or more cutaneous neurofibromas measuring 0.5-1.2cm in greatest diameter, present on thorax/abdomen or upper or lower limbs;

• If a woman of childbearing potential, is willing to use a medically acceptable form of contraception (in the judgment of the investigator) for the duration of the study;

• Is able to understand the informed consent form describing the risks of this study, and voluntarily signs the informed consent document;

• Is able to understand and comply with the requirements of the protocol.

Exclusion Criteria:

• Surgical, medical, or investigative treatment for any of the 6 target cutaneous neurofibromas to be evaluated in the study within three months prior to the baseline visit;

• Active infection (bacterial, viral, or fungal) requiring systemic antibiotics within two weeks of the baseline visit;

• Pregnancy or breastfeeding;

• Immunocompromised because of a medical condition;

• Known hypersensitivity to diclofenac or any other NSAID;

• Known hypersensitivity to aspirin;

• has a known hypersensitivity to mannitol, sodium metabisulphite, benzyl alcohol, or propylene glycol;

• Known hypersensitivity to lidocaine;

• Currently receiving or has received with 2 weeks of screening an NSAID (including diclofenac), a COX-2 inhibitor, cyclosporine, methotrexate, an oral anti-diabetic, lithium, digoxin, diuretics, anticoagulants (such as warfarin), or a quinolone antibiotic; except for intralesional diclofenac, these medications will not be allowed during the study; low-dose aspirin used for cardioprotective effects will be allowed;

• Any history of hepatic (including hepatic porphyria) or renal disease resulting in ongoing compromised hepatic or renal function;

• History of a bleeding/coagulation disorder;

• History of gastrointestinal (gastric or intestinal) ulcer disease, Crohn's disease, or ulcerative colitis;

• Laboratory examination at screening that reveals in the opinion of the investigator significant, unstable, and/or untreated renal, hepatic, or metabolic disease/dysfunction;

• White blood cell count at screening that is less than 3000, or a platelet count at screening that is less than 150,000;

• Laboratory evaluation at screening that shows the hemoglobin lower than the lower limit of normal for the laboratory utilized;

• Under treatment for a medical condition that, in the opinion of the investigator, may interfere with the safety of the experimental treatment or with the evaluation of efficacy, including but not limited to cardiovascular and/or respiratory disease;

• Subject is not, in the opinion of the investigator, capable of giving informed consent to participate in the study;

• Subject has received an investigational therapy or procedure for any reason within 30 days prior to screening.